Código QR (código de barras bidimensional)

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib

Abstract We present the case of a 34‐year‐old Japanese man with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer and brain metastases. After central nervous system (CNS) disease progression with alecintib and brigatinib, treatment with lorlatinib resulted in a good intracranial r...

ver descrição completa

Na minha lista:
Principais autores: Yuki Sato, Yoshiharu Sato, Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, Keisuke Tomii
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2024-08-01
coleção:Thoracic Cancer
Assuntos:
ALK
brigatinib
CNS penetration
lorlatinib
non‐small cell lung cancer
Acesso em linha:https://doi.org/10.1111/1759-7714.15395
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados